We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Biological Therapy for Inflammatory Bowel Diseases: Screening Prior to Initiating and How to Proceed When Surgery Is Necessary

Maria de Lourdes Setsuko Ayrizono,

Priscilla de Sene Portel Oliveira and João José Fagundes

Abstract

Biological therapy has revolutionized the management of inflammatory bowel disease (IBD) in the last 30 years. However, these drugs have side effects and adverse events. Before starting this therapy, it is necessary to screen for specific infectious diseases and monitoring protocols. Screening for human immunodeficiency virus, hepatitis C, hepatitis B, and *Mycobacterium tuberculosis* infections must be included. In addition, vaccination should be checked and updated if necessary. Despite the advent of biological therapy, a significant number of patients with IBD will need surgery in their lifetime due to either clinical intractability or disease complications. Many of them will be on biological therapy, and there is a considerable controversy about adverse effects of biologics on surgical outcomes. In this chapter, we will approach the screening required to start this therapy and how to proceed when surgery is necessary in these patients.

Keywords: inflammatory bowel disease, surgery, biologic agents, complications, infectious diseases, vaccines

1. Introduction

Biological therapy brought a better control of inflammatory bowel diseases (IBD). However, its use requires specific care before the beginning and during the treatment. Some essential points in its management have raised discussions.

We address the needs before starting the biological therapy and how to proceed when surgery is required. A brief review of what is necessary before the use of these drugs is also provided.

The management of other immunosuppressive agents such as corticosteroids, azathioprine, 6-mercaptopurine, and methotrexate is not covered in this chapter.

2. Pre-exposure biological therapy evaluations

The general recommendations include screening patients for risk factors of infection [1]:

- Comorbidities (e.g., transplant history, malignancy, renal or liver failure, diabetes mellitus)
- Age
- Occupation
- History of travel to areas of endemic diseases
- High-risk sexual activity, drug abuse
- Exposure to tuberculosis
- Blood transfusion

Patients receiving treatment with therapeutic monoclonal antibodies (specifically the tumor-necrosis-factor alpha inhibitors) are considered immunodeficient [2]. Therefore, before the onset of biological therapy, we should screen for some diseases, and the patients should be properly immunized [3–5].

Screening for human immunodeficiency virus infection (HIV), hepatitis C (HVC), hepatitis B (HVB), and *Mycobacterium tuberculosis* infection for all patients must be performed prior to starting biological therapy [1, 4–6].

Because of the risk and the severity of infections, which are increased in HIV-infected patients receiving biological therapy, they should be closely monitored. Biological therapy is not contraindicated in HIV-infected patients [4].

Screening of HVC in some European countries is not recommended because of its low prevalence and the fact that patients with HVC can be treated with biological therapy [5]. However, immunomodulators may influence active chronic HVC infection and may worsen liver function when concomitant infection with hepatitis B (concomitant HVB and HVC infection is common in some regions of the world) [4].

Every patient with hepatitis B negative tested (HBsAg, anti-HABs, and anti-HBcAb negatives) should be vaccinated before starting biological therapy. One to two months after the last dose of vaccine, patients should have their serological response evaluated. If infection is present by testing before vaccination, other specific tests should be performed, and the patient should be evaluated by a specialist for the need of treatment. The importance of care in relation to HVB infection consists in the fact that reactivation of HBV is a well-described complication of immunosuppression [4, 5, 7].

One infectious agents which should get more attention before the beginning of the biological therapy is *Mycobacterium tuberculosis*, because the reactivation of latent tuberculosis is increased and more severe in patients who follow this therapy. Proper latent tuberculosis search is performed by an assessment of an exposure history, skin test (PPD-tuberculosis skin test), interferon gamma release assay (IGRA), and chest X-ray, according to local prevalence and national

recommendations. Complete therapeutic regimen for latent tuberculosis must be initiated if identified after the screening examination and the biological therapy should be delayed [4, 5]. This full latent tuberculosis investigation can be modified or even indicated only if some exposure is suspected depending on where the patient lives. In this case, regional guidelines for prophylaxis must be followed. Only 22 countries worldwide represent 80% of the world's incidence. Therefore, local variations in the tuberculosis screening are accepted [4–6, 8].

If results of IGRA test or PPD are negative, they should be repeated, but there is no consensus as to how long [5].

Despite the variations in relation to screening for latent tuberculosis, when an alteration in the PPD test (≥ 5 mm) is found, the prophylaxis with isoniazid or appropriated antituberculous therapy must be initiated and maintained for 6 months. After at least 4 weeks with the use of the medication, we can initiate biological therapy [6].

3. Vaccination

It is worth noting that the patient's entire history of vaccination must be checked. If they did not receive the vaccines, they must be updated. Attention should be given, also to the recommended waiting period between each vaccine and the initiation of therapy.

In addition to the hepatitis B vaccine, the patient should also receive the following vaccines before starting the treatment with biological therapy [4–7, 9]:

- Varicella zoster virus (VZV)—if lacking clear history of chickenpox, shingles or if past vaccination history is uncertain
- Tetanus and diphtheria toxoid—every 10 years
- Human papilloma virus—according to national guidelines
- Zoster vaccine—for immunocompetent individuals over 60 years old
- Influenza virus—annual vaccination for all patients
- Hepatitis A—in endemic areas
- Pneumococcal (PPSV 23 and PCV13 vaccines)—every 3–5 years
- Meningococcal—for certain at-risk individuals (college students living in residential housing, military recruits, and immunosuppressed patients like asplenia, HIV, and complement deficiency)

It is important to emphasize that immunosuppressed patients do not respond properly to immunization. In addition, patients receiving biological therapy cannot be vaccinated with live attenuated virus (varicella zoster, yellow fever, measles, mumps, and rubella) [9].

A brief algorithm for preparing the patient for biological therapy is outlined in **Figure 1**.

Figure 1.
Algorithm for preparing the patient for biological therapy.

4. Biological therapy and surgery

When the screening and prophylaxis prior to initiating biological therapy involve numerous details regarding each disease that should be treated or prevented, the issue regarding biological therapy use and performing surgery can become even more complex. This complexity is due to the difficult analysis of patients since the groups submitted to surgery are extremely heterogeneous.

Despite the increasing number of available biological agents available, many patients will require operation due to intractability or complications of IBD. In a systematic review and meta-analysis of population-based studies, Frolkis et al. [10] showed that the risk of intestinal surgery among patients with IBD has decreased over the past six decades. They concluded that the risk of surgery in Crohn’s disease after 1, 5, and 10 years of diagnosis was 16.3, 33.3, and 46.6%, respectively, and in ulcerative colitis was 4.9, 11.6, and 15.6%, respectively.

In this way, many IBD patients will be on biological therapy when surgery is indicated. Literature data are conflicted with regard to the preoperative management of biological therapy in IBD surgery. Several large single-center studies and systematic reviews have found an increased risk of infectious complications with the use of anti-TNF preoperatively [11–14], whereas others have not [15–20].

These inconsistent results may be due to single institution experience, different duration of biological therapy, different periods between the last biologic dose and surgery, and concomitance with use of immunosuppressive agents and besides, may be a reflection of the severity of the disease and not the biological itself [16, 18, 21, 22].

Most studies use a 3-month cutoff to include patients in the anti-TNF group, but the serum level of the drug should also be taken into account [22]. Lau et al. [23] observed in their study that 53% of the IBD patients using preoperative anti-TNF had no detectable drug level at the time of surgery and it was more frequent in the ulcerative colitis group.

Regarding ulcerative colitis, the results are also conflicting with some studies showing increase in postoperative complications [24], while others show no association in preoperative anti-TNF therapy and increased risk of infectious and noninfectious complications after surgery [25].

Lightner et al. [26], in a retrospective multicenter cohort study, observed that IBD patients (Crohn's disease and ulcerative colitis) treated with vedolizumab had increased risk of postoperative surgical site infection and mucocutaneous separation of the diverting stoma as compared with anti-TNF-treated patients. They studied 146 patients who received vedolizumab 12 weeks before abdominal surgery and 289 patients who received anti-TNF therapy. However, two systematic reviews and meta-analysis [27, 28] did not find increased risks of postoperative complications with the use of vedolizumab when compared to either preoperative anti-TNF therapy or no biological therapy. Studies regarding the use of ustekinumab comparing with anti-TNF therapy also demonstrated no increase in the risk of postoperative complications [29, 30].

The occurrence of infectious and noninfectious complications after surgery in patients with IBD depends on several factors besides biological therapy. Among them one can mention the concomitance of the use of other medications, especially corticosteroids; the very severity of the disease; anemia, marked malnutrition in these patients, and smoking which greatly influence the occurrence of these complications [31]. Literature dates are conflicting, and in most studies, the patients and disease are heterogeneous. In addition, the time of exposure to the biological, the

Figure 2. Biological therapy and surgery. Source: Adapted from Lightner AL. Perioperative management of biologic and immunosuppressive medications in patients with Crohn's disease. *Dis Colon Rectum* 2018;61:428-31.

interval between the last dose and the surgery, the serum level of the medication, and drug pharmacokinetic should be considered.

For patients who are receiving biological therapy and will undergo abdominal surgery, we should consider [32] the following:

- Discontinue the medication 4 weeks before operation for anti-TNF- α and ustekinumab and 4–8 weeks before for vedolizumab.
- The medication should be reintroduced after 4 weeks, if necessary.
- For urgent situation, there is no need to delay the operation. The increased risks of infectious complications do not outweigh the risk of delaying surgery.
- Consider derivative ileostomy in emergency surgery and severely malnourished patients (serum albumin <3 g/L, body weight loss >10%) and/or concomitant use of corticosteroids (**Figure 2**).

Author details

Maria de Lourdes Setsuko Ayrizono^{1*}, Priscilla de Sene Portel Oliveira² and João José Fagundes¹

¹ Surgery Department, Colorectal Surgery Unit, School of Medical Sciences, University of Campinas, São Paulo, Brazil

² School of Medical Sciences, University of Campinas, São Paulo, Brazil

*Address all correspondence to: luayrizono@terra.com.br

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

- [1] Ponzo MG, Hong CH. A dermatologist's guide to infection screening prior to initiating immunosuppressive therapy. *Skin Therapy Letter*. 2017;**22**(1):8-11
- [2] Available at: <https://www.cdc.gov/mmwr/previent/mmwrhtml/rr5515a1htm>
- [3] Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guideline for assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *Journal of Crohn's and Colitis*. 2019;**13**(2):144-64K
- [4] Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowwies Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *Journal of Crohn's and Colitis*. 2014;**8**(6):443-468
- [5] Nordgaard-Lanssen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, et al. Guidelines for information prior to initiating anti-TNF-alpha treatment. *Danish Medical Journal*. 2012;**59**(7):C4480
- [6] Kane S. Preparing the patient for immunosuppressive therapy. *Current Gastroenterology Reports*. 2010;**12**: 502-506
- [7] Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel diseases. *World Journal of Gastroenterology*. 2013;**19**(9): 1349-1353
- [8] Organization WH. Global Tuberculosis Central 2017. Geneva: World Health Organization; 2017
- [9] Zullo S, Farrar F. Updates on vaccinating the inflammatory bowel disease patient. *Expert Review of Gastroenterology & Hepatology*. 2019;**13**(3):229-239
- [10] Frolkis AD, Aykerman J, Negron ME, deBruyn J, Jette N, Fiest KM, et al. Risk of surgery for IBD has decreased over time: A systematic review and meta-analysis of population-based studies. *The American Journal of Gastroenterology*. 2014;**109**:1739-1748
- [11] Brouquet A, Maggiori L, Zerbib P, Lefevre JH, Renost Q, Germain A, et al. Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: Results of a prospective nationwide cohort. *Annals of Surgery*. 2018;**267**:221-228
- [12] Ahmed Ali U, Martin ST, Rao AD, Kiran RP. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease. *Diseases of the Colon and Rectum*. 2014;**57**(5):663-674
- [13] Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn's disease. *Inflammatory Bowel Diseases*. 2015;**21**(6):1472-1477
- [14] Scarpa M, Martinato M, Bertini E, Da Roit A, Pozza A, Ruffolo C, et al. Intestinal surgery for Crohn's disease: Role of preoperative therapy in postoperative outcome. *Digestive Surgery*. 2015;**32**:243-250
- [15] Marchal L, R'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of postoperative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study. *Alimentary Pharmacology & Therapeutics*. 2004;**19**:749-754
- [16] Waterman M, Xu W, Dinani A, Steinhart AH, Croitoru K, et al.

Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. *Gut*. 2013; **62**:387-394

[17] Asfshar SE, Nikfar S, Rezaire A, Abdollahi M. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and postoperative complications in patients with inflammatory bowel disease. *Archives of Medical Science*. 2011; **7**(6): 1000-1012

[18] Bafford AC, Powers S, Ha C, Kruse D, Gorfine SR, Chessin DB. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease. *Journal of Clinical Gastroenterology*. 2013; **47**:491-495

[19] Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: Effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. *Alimentary Pharmacology & Therapeutics*. 2012; **36**(10):922-928

[20] Rosenfeld G, Qian H, Bressler B. The risk of postoperative complication following preoperative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: A systematic review and meta-analysis. *Journal of Crohn's & Colitis*. 2013; **7**(11): 868-877

[21] McKenna NP, Habermann EB, Glasgow AE, Dozois EJ, Lighner AL. Intra-abdominal sepsis after ileocolic resection in Crohn's disease: The role of combination immunosuppression. *Diseases of the Colon and Rectum*. 2018; **61**(12):1393-1402

[22] Zaghivan K, McGovern D, Fleshner P. Should biologic agents be stopped before surgery for inflammatory bowel disease? *Expert*

Review of Gastroenterology & Hepatology. 2015; **9**(3):269-272

[23] Lau C, Dubinski M, Melmed G, Vasiliauskas S, Berel D, McGovern D, et al. The impact of preoperative serum anti-TNF α therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. *Annals of Surgery*. 2015; **261**(3):487-496

[24] Kulaylat AS, Kulaylat AN, Schaefer EW, Tinsley A, Williams E, Koltun W, et al. Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis. *JAMA Surgery*. 2017; **152**(8):e171538

[25] Zitan E, Milgron R, Ma GW, Wong-Chong N, O'Connor B, McLeod RS, et al. Preoperative anti-tumor necrosis factor therapy in patients with ulcerative colitis is not associated with an increased risk of infectious and noninfectious complications after ileal pouch-anal anastomosis. *Inflammatory Bowel Diseases*. 2016; **22**(10):2442-2447

[26] Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: Retrospective multicenter cohort study. *Inflammatory Bowel Diseases*. 2018; **24**(4):871-876

[27] Law CCY, Narula A, Lightner AL, McKenna NP, Colombel JF, Narula N. Systematic review and meta-analysis: Preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. *Journal of Crohn's & Colitis*. 2018; **12**(5):538-545

[28] Yung DE, Horesh N, Lightner AL, Bem-Horin S, Eliakim R, Koulaouzidis A, et al. Systematic review and meta-analysis: Vedolizumab and

postoperative complications in
inflammatory bowel disease.
Inflammatory Bowel Diseases. 2018;
24(11):2327-2328

[29] Lightner AL, McKenna NP, Tse CS,
Hyman N, Smith R, Ovsepyan G, et al.
Postoperative outcomes in
ustekinumab-treated patients
undergoing abdominal operations for
Crohn's disease. *Journal of Crohn's &
Colitis*. 2018;**12**(4):402-407

[30] Shim HH, Ma C, Kotze PG,
Seow CH, Al-Farhan H, Al-Darmaki AK,
et al. Preoperative ustekinumab
treatment is not associated with
increased postoperative complications
in Crohn's disease: A Canadian multi-
Centre observational cohort study.
*Journal of the Canadian Association of
Gastroenterology*. 2018;**1**(3):115-123

[31] Hansen TM, Targownik LE,
Karimuddin A, Leung Y. Management
of biological therapy before elective
inflammatory bowel disease surgeries.
Inflammatory Bowel Diseases. 2019;**25**
(10):1613-1320. DOI: 10.1093/ibd/
izz002

[32] Lightner AL. Perioperative
management of biologic and
immunosuppressive medications in
patients with Crohn's disease. *Diseases
of the Colon and Rectum*. 2018;**61**:
428-431